Patients with moderate and severe meibomian gland dysfunction (MGD) may benefit from topical loteprednol etabonate and eyelid scrubs with warm compresses, according to researchers in South Korea.
Patients with moderate and severe meibomian gland dysfunction (MGD) may benefit from topical loteprednol etabonate and eyelid scrubs with warm compresses, according to researchers in South Korea. They found the treatment well-tolerated and efficacious, with beneficial effects particularly manifesting after 1 month.
In a study published online in the American Journal of Ophthalmology, the researchers conducted a randomized, controlled trial of two groups of patients with moderate and severe MGD. Group I (34 eyes) received topical loteprednol etabonate and eyelid scrubs with warm compresses; Group II (36 patients) used eyelid scrubs and warm compresses alone. The patients were assessed before treatment and at 1 and 2 months of treatment.
In Group I, the researchers found significant decreases in the levels of interleukin (IL)-6, IL-8, and IL-1β; the researchers cited a remarkable observed decrease in these cytokines between pre-treatment measurements and measurements taken after 1 month of treatment. Patients in Group II experienced significant decreases in the levels of IL-6 and IL-8.
Compared with the patients in Group II, patients in Group I showed superior improvements in the clinical outcomes measured, including tear film break-up time, corneal and conjunctival fluorescein staining, and meibum quality after 1 month of treatment.
In addition, patients in Group I displayed a more remarkable improvement in meibomian gland expressibility and MGD stage reduction than those in Group II.
To read an abstract of the study, click here.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.